NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Closure of Trading Window30-06-2022
NATCO PHARMA LTD. - 524816 - Disclosure Of Related Party Transactions For The Half Year Ended 31 March, 2022
Disclosure of Related Party Transactions for the half year ended 31 March, 2022NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Q4 FY22 Investor PresentationNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q4 FY 2022 Earnings Call TranscriptNatco Pharma launches first generic of Nexavar in the US
The product will be launched by Hyderabad-based Natco Pharma's commercial partner, ViatrisNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO Announces Launch of First Generic Version of Nexavar(r) (Sorafenib) Tablets in the U.S. MarketNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Recording of Analysts/Institutional Investor Meet/Con. Call held on 31st May, 2022Earnings Call for Q4FY22 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News paper publication of Audited Results for the quarter and year ended 31st March 2022